Australia's most trusted
source of pharma news
Monday, 20 May 2024
Posted 7 May 2024 PM
IDT Australia's plans to build the nation's first commercial antibody-drug-conjugate (ADC) facility have been backed by the Victorian Government, offering partial funding for the $3.8 million project.
While the exact dollar value of the grant is confidential, IDT Australia will receive funding over a 12-month period in three tranches.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.